Published in Lancet on July 20, 2009
Fluorescence Image-Guided Lymphadenectomy in Robotic Gastrectomy (IG-MIG) | NCT03931044
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
The Cholegas Study: safety of prophylactic cholecystectomy during gastrectomy for cancer: preliminary results of a multicentric randomized clinical trial. Gastric Cancer (2012) 2.06
Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One (2012) 1.70
Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol (2012) 1.66
Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer (2012) 1.60
Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer (2012) 1.48
MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.42
A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer (2014) 1.38
Treatment strategies in gastric cancer. Dtsch Arztebl Int (2011) 1.24
MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol (2012) 1.21
Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system. PLoS One (2012) 1.20
MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut (2014) 1.17
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol (2014) 1.13
Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One (2012) 1.12
Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget (2014) 1.11
A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev (2013) 1.09
Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun (2013) 1.09
Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer (2014) 1.07
miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer. Gastroenterol Res Pract (2012) 1.07
Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol (2012) 1.07
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol (2014) 1.07
A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer (2011) 1.06
Gastric cancer stem cells: a novel therapeutic target. Cancer Lett (2013) 1.04
Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med (2014) 1.04
Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. Mol Med (2012) 1.03
miR-874 Inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. J Gastroenterol (2013) 1.03
Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer. Nanoscale Res Lett (2012) 1.02
Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol (2015) 1.01
Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer (2014) 1.01
Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer (2014) 1.00
Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer (2012) 1.00
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol (2011) 1.00
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol (2015) 1.00
Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer. Theranostics (2015) 0.99
Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer. Oncogene (2015) 0.97
The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One (2015) 0.96
Treatment of early gastric cancer in the Western World. World J Gastroenterol (2014) 0.95
Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma. PLoS One (2015) 0.94
Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J Surg Oncol (2014) 0.93
Phase and size controllable synthesis of NaYbF4 nanocrystals in oleic acid/ionic liquid two-phase system for targeted fluorescent imaging of gastric cancer. Theranostics (2013) 0.93
Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells. Int J Oncol (2011) 0.93
Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One (2013) 0.92
A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLoS One (2013) 0.92
Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. Int J Clin Exp Pathol (2014) 0.91
Incidence, predictive factors, and clinical outcomes of acute kidney injury after gastric surgery for gastric cancer. PLoS One (2013) 0.91
Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. Mol Clin Oncol (2014) 0.91
Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer (2013) 0.90
Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer. Oncotarget (2015) 0.90
Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer. Oncogene (2011) 0.90
Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer (2011) 0.90
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer (2016) 0.90
An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des Devel Ther (2014) 0.89
Circulating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: a meta-analysis based on 42 articles. PLoS One (2014) 0.89
Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway. Cancer Biol Ther (2013) 0.89
Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer (2015) 0.89
miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) (2015) 0.89
MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget (2016) 0.88
Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci (2014) 0.88
Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. World J Gastroenterol (2014) 0.88
No association between single nucleotide polymorphisms in pre-mirnas and the risk of gastric cancer in Chinese population. Iran J Basic Med Sci (2014) 0.88
Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study. EBioMedicine (2016) 0.88
Gastric cancer. Lancet (2009) 0.87
Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling. PLoS One (2013) 0.87
Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer. PLoS One (2013) 0.87
Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling. J Cell Mol Med (2014) 0.87
Lymph node ratio is a better prognosticator than lymph node status for gastric cancer: A retrospective study of 138 cases. Oncol Lett (2013) 0.87
The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma. Oncol Rep (2012) 0.86
Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res (2014) 0.86
Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol (2013) 0.86
Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer. Int J Clin Exp Pathol (2015) 0.86
Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model. Oncotarget (2015) 0.86
Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget (2016) 0.86
Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer (2014) 0.85
Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy. BMC Cancer (2015) 0.85
Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican. Int J Biol Sci (2012) 0.85
Current role of minimally invasive approaches in the treatment of early gastric cancer. World J Gastroenterol (2014) 0.85
Prognostic value of the seventh AJCC/UICC TNM classification of non-cardia gastric cancer. World J Surg Oncol (2013) 0.85
The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget (2016) 0.85
Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chin J Cancer Res (2014) 0.84
Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol (2014) 0.84
LGR5 is a promising biomarker for patients with stage I and II gastric cancer. Chin J Cancer Res (2013) 0.84
MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer. Mol Cells (2013) 0.84
Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer (2012) 0.84
TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway. Int J Clin Exp Med (2015) 0.84
miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer. J Exp Clin Cancer Res (2015) 0.84
Beclin-1 expression is a significant predictor of survival in patients with lymph node-positive gastric cancer. PLoS One (2012) 0.84
Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer. Oncol Lett (2015) 0.84
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? Cancer Biol Ther (2015) 0.83
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. Br J Cancer (2014) 0.83
Cellular physiological approach for treatment of gastric cancer. World J Gastroenterol (2014) 0.83
Long noncoding RNAs in gastric cancer: functions and clinical applications. Onco Targets Ther (2016) 0.83
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget (2014) 0.83
rs11671784 G/A and rs895819 A/G polymorphisms inversely affect gastric cancer susceptibility and miR-27a expression in a Chinese population. Med Sci Monit (2014) 0.83
A synergistic interaction between transcription factors nuclear factor-κB and signal transducers and activators of transcription 3 promotes gastric cancer cell migration and invasion. BMC Gastroenterol (2013) 0.83
miR-183 inhibits invasion of gastric cancer by targeting Ezrin. Int J Clin Exp Pathol (2014) 0.83
MTA2 enhances colony formation and tumor growth of gastric cancer cells through IL-11. BMC Cancer (2015) 0.83
Impact on survival of the number of lymph nodes resected in patients with lymph node-negative gastric cancer. World J Surg Oncol (2015) 0.82
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer. Am J Cancer Res (2015) 0.82
Antitumor activity of cell-permeable RUNX3 protein in gastric cancer cells. Clin Cancer Res (2012) 0.82
The hallmarks of cancer. Cell (2000) 113.05
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Genetic instabilities in human cancers. Nature (1998) 22.76
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Helicobacter pylori infection and the development of gastric cancer. N Engl J Med (2001) 17.13
Surgeon volume and operative mortality in the United States. N Engl J Med (2003) 16.97
Japanese Classification of Gastric Carcinoma - 2nd English Edition - Gastric Cancer (1998) 16.63
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97
Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res (1992) 12.77
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med (1991) 11.98
Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med (2002) 11.14
Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet (2001) 11.06
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ (1991) 9.88
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 9.00
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer (2000) 8.85
Epidemiology of gastric cancer. World J Gastroenterol (2006) 7.67
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer (1999) 6.76
Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol (2004) 6.47
Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet (2008) 5.41
Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol (1993) 5.37
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut (2001) 4.97
Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol (2006) 4.90
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol (1997) 4.69
Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol (2006) 4.38
Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med (2000) 4.09
Gastric cancer treatment guidelines in Japan. Gastric Cancer (2002) 3.81
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys (1982) 3.05
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg (1988) 3.03
A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer (2006) 2.98
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet (2004) 2.95
Hospital volume and late survival after cancer surgery. Ann Surg (2007) 2.93
Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell (2006) 2.89
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer (2008) 2.84
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol (2004) 2.83
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol (2006) 2.42
Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer (1999) 2.36
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol (1985) 2.26
Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer (2007) 2.25
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys (1998) 2.20
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19
A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg (1994) 2.12
Sentinel node mapping during laparoscopic distal gastrectomy for gastric cancer. Surg Endosc (2007) 2.12
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res (2008) 2.08
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol (2007) 2.06
Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer. Ann Surg (2009) 2.04
Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg (1999) 2.00
Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer (1999) 1.99
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control (2008) 1.96
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol (2005) 1.93
The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet (1994) 1.92
Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg (2004) 1.87
IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys (2005) 1.84
Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res (2001) 1.83
Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol (2002) 1.81
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer (2003) 1.78
Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg (2006) 1.78
Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol (2007) 1.74
Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.68
Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer (2007) 1.67
E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat (1999) 1.65
Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg (1989) 1.64
Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol (2008) 1.62
Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med (2008) 1.62
EMR for early gastric cancer in Korea: a multicenter retrospective study. Gastrointest Endosc (2007) 1.59
Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. Radiology (2005) 1.56
Optimal locoregional treatment in gastric cancer. J Clin Oncol (2005) 1.54
Chemotherapy of advanced gastric cancer. Cancer Treat Rev (2007) 1.50
Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg (1989) 1.49
Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol (1984) 1.46
Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol (2002) 1.46
A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery (2002) 1.45
Gastric cancer in Europe. Br J Surg (2008) 1.45
Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg (2002) 1.43
Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys (2002) 1.41
Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene (2003) 1.40
Current status of minimal access surgery for gastric cancer. Surg Oncol (2007) 1.39
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol (2004) 1.39
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res (2005) 1.38
Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res (2008) 1.37
Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg (2000) 1.36
Laparoscopic gastrectomy with lymph node dissection for gastric cancer. Gastric Cancer (2006) 1.35
Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol (2006) 1.33
Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther (2007) 1.29
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol (2010) 6.60
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 5.75
The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg (2007) 4.22
Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol (2002) 4.02
The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol (2011) 3.24
Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology (2008) 3.18
Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol (2002) 3.09
Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01
Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol (2011) 2.67
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol (2011) 2.58
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol (2014) 2.39
Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis. Lancet Oncol (2011) 2.36
Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol (2005) 2.33
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol (2010) 2.29
External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer. J Natl Cancer Inst (2014) 2.26
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol (2012) 2.20
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol (2013) 2.17
Optical image-guided surgery--where do we stand? Mol Imaging Biol (2011) 2.15
Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. Eur J Surg Oncol (2013) 2.12
A multivariate analysis of limiting factors for stoma reversal in patients with rectal cancer entered into the total mesorectal excision (TME) trial: a retrospective study. Lancet Oncol (2007) 2.12
Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. J Pathol (2002) 2.11
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. Eur J Cancer (2012) 2.07
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest (2004) 2.05
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol (2010) 2.04
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA (2012) 2.00
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: a first in human experience. J Urol (2013) 1.97
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat (2011) 1.89
Causes of fecal and urinary incontinence after total mesorectal excision for rectal cancer based on cadaveric surgery: a study from the Cooperative Clinical Investigators of the Dutch total mesorectal excision trial. J Clin Oncol (2008) 1.87
The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol (2012) 1.87
Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat (2010) 1.83
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer (2011) 1.76
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
Near-infrared fluorescence-guided resection of colorectal liver metastases. Cancer (2013) 1.71
EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol (2004) 1.68
Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer (2007) 1.67
Optimal locoregional treatment in gastric cancer. J Clin Oncol (2005) 1.54
Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc (2012) 1.51
The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc (2010) 1.46
Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol (2007) 1.45
PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res (2009) 1.45
Metastases of colorectal carcinoma: comparison of soft- and hard-copy helical CT interpretation. Radiology (2003) 1.45
Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients. Breast Cancer Res Treat (2011) 1.43
HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol (2010) 1.38
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38
Estimation and prediction in a multi-state model for breast cancer. Biom J (2006) 1.36
Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer (2006) 1.36
Self-reports of health-care utilization: diary or questionnaire? Int J Technol Assess Health Care (2005) 1.35
Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics (2005) 1.34
Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer (2005) 1.34
Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res Treat (2013) 1.33
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol (2011) 1.31
Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review. Dis Colon Rectum (2008) 1.31
Lymph node retrieval in rectal cancer is dependent on many factors--the role of the tumor, the patient, the surgeon, the radiotherapist, and the pathologist. Am J Surg Pathol (2009) 1.29
The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res (2010) 1.28
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27
Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol (2005) 1.26
Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol (2012) 1.26
Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using invisible near-infrared fluorescence light. Ann Surg Oncol (2010) 1.24
The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer (2009) 1.24
Near-infrared fluorescence imaging of liver metastases in rats using indocyanine green. J Surg Res (2011) 1.23
Optimization of near-infrared fluorescent sentinel lymph node mapping in cervical cancer patients. Int J Gynecol Cancer (2011) 1.22
Cost measurement in economic evaluations of health care: whom to ask? Med Care (2004) 1.22
Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. Ann Surg (2007) 1.20
Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol (2008) 1.20
Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer (2012) 1.18
Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer. Breast Cancer Res Treat (2010) 1.17
p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases. Clin Exp Metastasis (2004) 1.17
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol (2012) 1.15
A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg (2009) 1.14
USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology (2008) 1.14
Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light. J Hepatobiliary Pancreat Sci (2012) 1.14
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res (2009) 1.14
NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer (2012) 1.11
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol (2011) 1.11
Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecol Oncol (2012) 1.10
Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol (2010) 1.09
Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat (2012) 1.09
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) (2014) 1.09
Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am J Obstet Gynecol (2011) 1.09
Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes? Radiology (2009) 1.06
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat (2010) 1.06
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr) (2011) 1.06
Novel intraoperative near-infrared fluorescence camera system for optical image-guided cancer surgery. Mol Imaging (2010) 1.05
Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter (2010) 1.05
The gastric cancer treatment controversy. J Clin Oncol (2003) 1.04
High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch (2009) 1.04
Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol (2004) 1.04
Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol (2006) 1.03
Intraoperative near-infrared fluorescence imaging of parathyroid adenomas with use of low-dose methylene blue. Head Neck (2013) 1.01
Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res (2007) 1.01
Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat (2008) 1.01
Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. BMJ (2004) 1.01